II. Indications
- High risk pregnancy (see efficacy below)
- See Peripartum Risk to the Fetus
- Antepartum factors
- Conditions affecting placental insufficiency
- Known fetal anomaly
- Maternal Preeclampsia or Gestational Hypertension
- Maternal Type 1 Diabetes Mellitus
- Fetal Growth Retardation suspected
- Intrapartum factors
- Meconium present
- Tachysystole
- Intrauterine Infection
- Vaginal Bleeding
- Uterine stimulant (i.e. Oxytocin) use for Labor Induction or augmentation
- Low risk patient with concerning on Structured Intermittent Auscultation (SIA)
- Irregular Fetal Heart Rate
- Fetal Tachycardia (>160 bpm for >10 minutes)
- Fetal Bradycardia (<110 bpm for >10 minutes)
- Recurrent fetal decelerations after contractions (>50% of contractions)
- Prolonged deceleration (2-10 minutes)
- External monitoring is not possible
- Maternal body habitus
- Fetal Position interferes with monitoring
III. Adverse Effects
- See Efficacy below (including False Positive Rate)
- Requires Amniotomy and increased risk of Chorioamnionitis, vertical transmission HSV and Viral Hepatitis
IV. Technique
- Intrauterine scalp electrode placement
- Intrauterine pressure catheter placement
V. Efficacy: Continuous Electronic Fetal Monitoring (CEFM)
- CEFM does not significantly improve fetal outcome
- Only measurable benefits
- Fewer Neonatal Seizures
- Good tracing is reassuring for good outcome
- No benefit in APGAR Scores
- No decrease in NICU admissions
- No change in perinatal death rate
- No reduction in Cerebral Palsy
- Non-reassuring tracing does not predict bad outcome
- False Positive Rate 99.8% if ominous tracing
- Late Decelerations
- Decreased variability
- Only measurable benefits
- CEFM increases the risk of surgical intervention (False Positive for fetal acidosis in two thirds of cases)
- Increases ceserean rate by 20%
- Increases operative Vaginal Delivery rate
- Consider Informed Consent for CEFM
- CEFM may be indicated in high risk pregnancies
- Consider intermittent monitoring if low risk